483 Woodfield Pharmaceutical Jan 2020

483 Woodfield Pharmaceutical Jan 2020

Camerson Moore FDA$119.00 - Available Now

FDA investigators audited the Woodfield Pharmaceutical - Houston, TX, United States facility and issued inspectional observations (via FDA 483) on 24 Jan 2020.

Product details

  • Category: Human Drugs
  • Inspection end: 24 Jan 2020
  • Location: Houston, United States
  • FEI: 1628196
Add To Cart